DK1756096T3 - Indolylderivater som lever-X-receptormodulatorer - Google Patents

Indolylderivater som lever-X-receptormodulatorer

Info

Publication number: DK1756096T3
Authority: DK; Denmark
Prior art keywords: liver; receptor modulators; indolyl derivatives; indolyl; derivatives
Prior art date: 2004-05-03

Application number

DK05751959T

Other languages

Danish (da)

English (en)

Inventor

Henrietta Dehmlow

Bernd Kuhn

Narendra Panday

Hasane Ratni

Tanja Schulz-Gasch

Matthew Blake Wright

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-05-03

Filing date

2005-04-26

Publication date

2009-10-26

2005-04-26 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2009-10-26 Application granted granted Critical

2009-10-26 Publication of DK1756096T3 publication Critical patent/DK1756096T3/da

Links

125000001041 indolyl group Chemical group 0.000 title 1
102000004311 liver X receptors Human genes 0.000 title 1
108090000865 liver X receptors Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Indole Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK05751959T 2004-05-03 2005-04-26 Indolylderivater som lever-X-receptormodulatorer DK1756096T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP04101889		2004-05-03
PCT/EP2005/004454 WO2005105791A1 (en)	2004-05-03	2005-04-26	Indolyl derivatives as liver-x-receptor modulators

Publications (1)

Publication Number	Publication Date
DK1756096T3 true DK1756096T3 (da)	2009-10-26

Family

ID=34970495

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK05751959T DK1756096T3 (da)	2004-05-03	2005-04-26	Indolylderivater som lever-X-receptormodulatorer

Country Status (26)

Country	Link
US (2)	US7173048B2 (de)
EP (1)	EP1756096B1 (de)
JP (1)	JP4682192B2 (de)
KR (1)	KR100893449B1 (de)
CN (1)	CN1950365A (de)
AR (1)	AR049497A1 (de)
AT (1)	ATE439357T1 (de)
AU (1)	AU2005238176B2 (de)
BR (1)	BRPI0510599A (de)
CA (1)	CA2564563C (de)
DE (1)	DE602005015962D1 (de)
DK (1)	DK1756096T3 (de)
ES (1)	ES2329489T3 (de)
HR (1)	HRP20090533T1 (de)
IL (1)	IL178767A0 (de)
MX (1)	MXPA06012683A (de)
MY (1)	MY139571A (de)
NO (1)	NO20065503L (de)
NZ (1)	NZ550447A (de)
PL (1)	PL1756096T3 (de)
PT (1)	PT1756096E (de)
RU (1)	RU2368612C2 (de)
SI (1)	SI1756096T1 (de)
TW (1)	TWI287537B (de)
WO (1)	WO2005105791A1 (de)
ZA (1)	ZA200608886B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7790745B2 (en)	2005-10-21	2010-09-07	Bristol-Myers Squibb Company	Tetrahydroisoquinoline LXR Modulators
US7741317B2 (en)	2005-10-21	2010-06-22	Bristol-Myers Squibb Company	LXR modulators
US20070225285A1 (en) *	2005-11-04	2007-09-27	Amira Pharmaceuticals, Inc.	5-lipoxygenase-activating protein (flap) inhibitors
US20070219206A1 (en) *	2005-11-04	2007-09-20	Amira Pharmaceuticals, Inc.	5-lipoxygenase-activating protein (flap) inhibitors
GB2431927B (en) *	2005-11-04	2010-03-17	Amira Pharmaceuticals Inc	5-Lipoxygenase-activating protein (FLAP) inhibitors
US20070244128A1 (en) *	2005-11-04	2007-10-18	Amira Pharmaceuticals, Inc.	5-lipoxygenase-activating protein (flap) inhibitors
US7977359B2 (en) *	2005-11-04	2011-07-12	Amira Pharmaceuticals, Inc.	5-lipdxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) *	2005-11-04	2013-03-19	Panmira Pharmaceuticals, Llc	5-lipoxygenase-activating protein (FLAP) inhibitors
CN101528214B (zh)	2006-08-24	2013-06-05	田纳西大学研究基金会	取代的n-酰基苯胺及其使用方法
ES2452343T3 (es) *	2006-09-29	2014-04-01	Glaxosmithkline Llc	Compuestos de indol sustituidos
CN101663262B (zh)	2006-12-01	2014-03-26	百时美施贵宝公司	用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
WO2008137436A1 (en) *	2007-05-04	2008-11-13	Bristol-Myers Squibb Company	[6,5]-bicyclic gpr119 g protein-coupled receptor agonists
CN101668756A (zh)	2007-05-04	2010-03-10	百时美施贵宝公司	[6,6]和[6,7]-双环gpr119 g蛋白偶合受体激动剂
SI2170864T1 (sl) *	2007-07-17	2012-04-30	Bristol Myers Squibb Co	Piridon gpr119g proteinsko povezani receptorski antagonisti
KR100918814B1 (ko) *	2007-10-04	2009-09-25	건국대학교 산학협력단	인쇄방법을 이용한 세라믹 전자부품 고속제조방법
TW200920369A (en) *	2007-10-26	2009-05-16	Amira Pharmaceuticals Inc	5-lipoxygenase activating protein (flap) inhibitor
CN101970479A (zh) *	2008-03-17	2011-02-09	弗·哈夫曼-拉罗切有限公司	Lxr配体结合结构域(lxr lbd)晶体
JP5791500B2 (ja) *	2008-05-23	2015-10-07	パンミラファーマシューティカルズ，エルエルシー．	５−リポキシゲナーゼ活性化タンパク質阻害剤
TW201006821A (en)	2008-07-16	2010-02-16	Bristol Myers Squibb Co	Pyridone and pyridazone analogues as GPR119 modulators
US8546431B2 (en)	2008-10-01	2013-10-01	Panmira Pharmaceuticals, Llc	5-lipoxygenase-activating protein (FLAP) inhibitors
MX2012011460A (es)	2010-04-08	2012-11-23	Squibb Bristol Myers Co	Analogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119.
CA2798610A1 (en)	2010-05-06	2011-11-10	Bristol-Myers Squibb Company	Bicyclic heteroaryl compounds as gpr119 modulators
WO2011140161A1 (en)	2010-05-06	2011-11-10	Bristol-Myers Squibb Company	Benzofuranyl analogues as gpr119 modulators
RU2598842C2 (ru) *	2011-01-20	2016-09-27	Мерк Шарп Энд Домэ Корп.	Антагонисты рецептора минералокортикоидов
US9174965B2 (en)	2012-05-16	2015-11-03	Bristol-Myers Squibb Company	Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators
PT2872482T (pt)	2012-07-13	2020-09-22	Oncternal Therapeutics Inc	Método de tratamento de cancro de mama com modulador seletivo do recetor de andrógeno (sarm)
US9622992B2 (en)	2012-07-13	2017-04-18	Gtx, Inc.	Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10987334B2 (en)	2012-07-13	2021-04-27	University Of Tennessee Research Foundation	Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9969683B2 (en)	2012-07-13	2018-05-15	Gtx, Inc.	Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10258596B2 (en)	2012-07-13	2019-04-16	Gtx, Inc.	Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en)	2012-07-13	2017-08-29	Gtx, Inc.	Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en)	2012-07-13	2019-06-11	Gtx, Inc.	Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
WO2014139388A1 (en) *	2013-03-14	2014-09-18	Merck Sharp & Dohme Corp.	Novel indole derivatives useful as anti-diabetic agents
US9580422B2 (en)	2013-10-22	2017-02-28	Bristol-Myers Squibb Company	Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US10669296B2 (en)	2014-01-10	2020-06-02	Rgenix, Inc.	LXR agonists and uses thereof
CA3010883A1 (en)	2016-01-11	2017-07-20	The Rockefeller University	Methods for the treatment of myeloid derived suppressor cells related disorders
CN106187899B (zh) *	2016-06-28	2019-07-16	绍兴文理学院	一种氟代氮杂芳烃的合成方法
EP3487862A1 (de)	2016-07-22	2019-05-29	Bristol-Myers Squibb Company	Glucokinaseaktivatoren und verfahren zur verwendung davon
EP3713575A4 (de)	2017-11-21	2021-08-25	Rgenix, Inc.	Polymorphe und ihre verwendung
TWI748194B (zh)	2018-06-28	2021-12-01	德商菲尼克斯Ｆｘｒ有限責任公司	含有雙環核心部分之新穎lxr調節劑
US20200085810A1 (en)	2018-07-26	2020-03-19	Hoffmann-La Roche Inc.	Compounds for use in treating kidney disorders
CN110305141B (zh)	2019-07-18	2022-01-11	深圳市三启药物开发有限公司	一种螺(3,3’-异丙基吡咯烷氧化吲哚)类肝x受体调节剂及其制备方法和应用
HUE067466T2 (hu)	2019-12-13	2024-10-28	Inspirna Inc	Fémsók és alkalmazásuk
CN115028655B (zh) *	2022-05-20	2024-01-16	上海大学	一种2-三氟甲基-3-碘-吲哚类化合物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GR63361B (en) *	1976-06-24	1979-10-22	Du Pont	Preparation process of antihypertensive hexafluorohydroxyisopropyl bicyclic and tricyclic carbostyrils
US4251659A (en) *	1977-12-22	1981-02-17	E. I. Du Pont De Nemours And Company	Polyfluorohydroxyisopropyl-heterocyclic compounds
DK151884C (da) *	1979-03-07	1988-06-13	Pfizer	Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf
JPH0995482A (ja)	1995-09-29	1997-04-08	Shionogi & Co Ltd	α−置換酢酸を有する複素環誘導体、その製造用中間体ならびにそれを含有する農薬
WO1997019311A1 (en)	1995-11-17	1997-05-29	Form Rite	Bypass fitting for a transmission fluid cooler
AU2002342244B2 (en)	2001-05-15	2005-06-16	F. Hoffmann-La Roche Ag	Carboxylic acid substituted oxazole derivatives for use as PPAR-alpha and -gamma activators in the treatment of diabetes
US6472386B1 (en)	2001-06-29	2002-10-29	Kowa Co., Ltd.	Cyclic diamine compound with 5-membered ring groups
GB0216224D0 (en)	2002-07-12	2002-08-21	Glaxo Group Ltd	Compounds

2005
- 2005-04-26 JP JP2007511949A patent/JP4682192B2/ja not_active Expired - Fee Related
- 2005-04-26 RU RU2006142746/04A patent/RU2368612C2/ru not_active IP Right Cessation
- 2005-04-26 ES ES05751959T patent/ES2329489T3/es not_active Expired - Lifetime
- 2005-04-26 CA CA2564563A patent/CA2564563C/en not_active Expired - Fee Related
- 2005-04-26 AU AU2005238176A patent/AU2005238176B2/en not_active Ceased
- 2005-04-26 NZ NZ550447A patent/NZ550447A/en not_active IP Right Cessation
- 2005-04-26 SI SI200530765T patent/SI1756096T1/sl unknown
- 2005-04-26 DK DK05751959T patent/DK1756096T3/da active
- 2005-04-26 PT PT05751959T patent/PT1756096E/pt unknown
- 2005-04-26 AT AT05751959T patent/ATE439357T1/de active
- 2005-04-26 HR HR20090533T patent/HRP20090533T1/xx unknown
- 2005-04-26 EP EP05751959A patent/EP1756096B1/de not_active Expired - Lifetime
- 2005-04-26 CN CNA2005800142069A patent/CN1950365A/zh active Pending
- 2005-04-26 DE DE602005015962T patent/DE602005015962D1/de not_active Expired - Lifetime
- 2005-04-26 MX MXPA06012683A patent/MXPA06012683A/es active IP Right Grant
- 2005-04-26 KR KR1020067023014A patent/KR100893449B1/ko not_active Expired - Fee Related
- 2005-04-26 PL PL05751959T patent/PL1756096T3/pl unknown
- 2005-04-26 BR BRPI0510599-4A patent/BRPI0510599A/pt not_active IP Right Cessation
- 2005-04-26 WO PCT/EP2005/004454 patent/WO2005105791A1/en not_active Ceased
- 2005-04-27 US US11/115,942 patent/US7173048B2/en not_active Expired - Fee Related
- 2005-04-28 MY MYPI20051897A patent/MY139571A/en unknown
- 2005-04-29 AR ARP050101717A patent/AR049497A1/es unknown
- 2005-04-29 TW TW094113966A patent/TWI287537B/zh not_active IP Right Cessation
2006
- 2006-10-19 IL IL178767A patent/IL178767A0/en unknown
- 2006-10-25 ZA ZA200608886A patent/ZA200608886B/en unknown
- 2006-11-29 NO NO20065503A patent/NO20065503L/no not_active Application Discontinuation
- 2006-12-11 US US11/636,925 patent/US7485652B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
MY139571A (en)	2009-10-30
TWI287537B (en)	2007-10-01
MXPA06012683A (es)	2007-01-16
NZ550447A (en)	2010-06-25
WO2005105791A1 (en)	2005-11-10
US20050245515A1 (en)	2005-11-03
US20070099916A1 (en)	2007-05-03
KR100893449B1 (ko)	2009-04-17
EP1756096B1 (de)	2009-08-12
US7485652B2 (en)	2009-02-03
TW200606147A (en)	2006-02-16
BRPI0510599A (pt)	2007-11-20
AR049497A1 (es)	2006-08-09
DE602005015962D1 (de)	2009-09-24
CA2564563C (en)	2011-07-05
RU2006142746A (ru)	2008-06-10
ZA200608886B (en)	2008-06-25
IL178767A0 (en)	2007-02-11
HRP20090533T1 (hr)	2009-11-30
PT1756096E (pt)	2009-10-16
CN1950365A (zh)	2007-04-18
US7173048B2 (en)	2007-02-06
AU2005238176B2 (en)	2008-11-27
NO20065503L (no)	2007-01-24
JP4682192B2 (ja)	2011-05-11
ES2329489T3 (es)	2009-11-26
KR20070008678A (ko)	2007-01-17
EP1756096A1 (de)	2007-02-28
PL1756096T3 (pl)	2010-01-29
RU2368612C2 (ru)	2009-09-27
ATE439357T1 (de)	2009-08-15
CA2564563A1 (en)	2005-11-10
JP2007536300A (ja)	2007-12-13
SI1756096T1 (sl)	2009-10-31
AU2005238176A1 (en)	2005-11-10

Publication	Publication Date	Title
DK1756096T3 (da)	2009-10-26	Indolylderivater som lever-X-receptormodulatorer
CY2017008I2 (el)	2017-11-14	Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων
DK2094658T3 (da)	2012-02-13	Tetrahydrocyclopenta[B]indolforbindelser som androgenreceptormodulatorer
DK2069335T3 (da)	2013-02-18	Pyridin-3-ylderivater som immunomoduleringsmidler
DK2069336T3 (da)	2013-02-25	Pyridin-4-yl-derivater som immunomodulerende midler
DK1928845T3 (da)	2013-08-05	Aminodiazepiner som toll-lignende receptor-modulatorer
NO20051042L (no)	2005-03-31	Pyrimidylsulfonamidderivater som kemokinreseptormodulatorer
DK1668014T3 (da)	2009-04-20	Kondenserede heterocykliske forbindelser som serotoninreceptormodulatorer
ATE545631T1 (de)	2012-03-15	N-(2-benzyl)-2-phenylbutanamide als androgenrezeptormodulatoren
NO20070494L (no)	2007-03-23	Substituerte azepinderivater som serotoninreseptormodulatorer
DK2144897T3 (da)	2011-02-07	8-Oxy-quinolinderivater som bradykinin B2-receptormodulatorer
DK1789041T3 (da)	2008-09-08	Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
DK1833799T3 (da)	2009-01-19	3-phenyl-pyrazol derivater, som modulatorer af 5-HT-2a-serotonin receptor nyttig til behandlingen af sygdomme relateret hertil
DK1735286T3 (da)	2012-04-02	Tetrahydroindazoler som cannabinoidmodulatorer
DK1797042T3 (da)	2009-03-02	Indozolonderivater som 11B-HSD1-inhibitorer
DK1856110T3 (da)	2011-08-15	Oxyindol derivater som 5HT4-receptor agonister
DK1891075T3 (da)	2011-12-19	Tricykliske spiroderivater som CRTH2-modulatorer
EP1841794A4 (de)	2008-10-29	Adam-9-modulatoren
DK1802307T3 (da)	2008-06-30	Pyrrolidinderivater som histamin-receptor-ligander
DK1809624T3 (da)	2014-01-20	Pyrimidinsulfonamidderivater som kemokinreceptor-modulatorer
DK1904477T3 (da)	2009-03-16	Indol-3-carbonyl-spiro-piperodom-derivater som V1A-receptorantagonister
DK2447252T3 (da)	2020-03-16	Theramuteinmodulatorer
EP1915162A4 (de)	2009-08-26	Modulatoren
ATE396998T1 (de)	2008-06-15	Tetrazyklische imidazobenzodiazepine als gaba- rezeptormodulatoren
DK1912976T3 (da)	2009-01-26	Indol-3-YL-carbonyl-piperidin-benzoimidazolderivater som V1A-receptorantagonister